Gross Profit Comparison: Merck & Co., Inc. and Bausch Health Companies Inc. Trends

Merck's profit growth outpaces Bausch Health's stability.

__timestampBausch Health Companies Inc.Merck & Co., Inc.
Wednesday, January 1, 2014600890000025469000000
Thursday, January 1, 2015785380000024564000000
Friday, January 1, 2016706300000025916000000
Sunday, January 1, 2017617600000027347000000
Monday, January 1, 2018602900000028785000000
Tuesday, January 1, 2019625100000032728000000
Wednesday, January 1, 2020577800000027900000000
Friday, January 1, 2021604000000035078000000
Saturday, January 1, 2022576000000041872000000
Sunday, January 1, 2023619800000043989000000
Loading chart...

Unleashing insights

Gross Profit Trends: Merck & Co., Inc. vs. Bausch Health Companies Inc.

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, Merck & Co., Inc. has consistently outperformed Bausch Health Companies Inc. in terms of gross profit. From 2014 to 2023, Merck's gross profit surged by approximately 73%, peaking at $44 billion in 2023. In contrast, Bausch Health's gross profit remained relatively stable, with a slight decline of around 1% over the same period, ending at $6.2 billion in 2023.

This stark contrast highlights Merck's robust growth trajectory, driven by strategic investments and a strong product pipeline. Meanwhile, Bausch Health's steady performance suggests a need for innovation and market expansion. As the pharmaceutical landscape continues to shift, these trends offer valuable insights into the financial health and strategic direction of these industry giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025